Skip to content
value.today

Biolase Technology Inc.

Total raised
$23 M
4 rounds on record
Latest round
$3 M
Dec 2023
First round on record
Jun 2011
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Biolase Technology Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2023$3 MNo. 4$2 to $10 million

Biolase Technology Inc.: Raise no. 4, Dec 2023

Investors in this round

1 investor had bought by the notice of Dec 20, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Common Warrants and Shares of Common Stock Underlying the Common Warrants
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$96,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jennifer R. Bright · Executive Officer
  • John R. Beaver · Executive Officer, Director
  • Carol Gomez Summerhays · Director
  • Jess T. Roper · Director
  • Jonathan R. Lord · Director
  • Kathleen T. O'Loughlin · Director
  • Kenneth P. Yale · Director
  • Martha T. Somerman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in no state named, and outside the US

Remarks in the notice

  • On the amounts: “The Issuer issued securities in a registered direct offering for gross proceeds of approximately $1.36 million and in a concurrent private placement issued warrants to purchase an aggregate of 2,221,880 shares of common stock”
  • On the use of proceeds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”

Signed by John R. Beaver, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 20, 2023. Read the notice at the SEC.

equity, optionsSEC
Jun 2020$7 MNo. 3$2 to $10 million

Biolase Technology Inc.: Raise no. 3, Jun 2020

Investors in this round

9 investors had bought by the notice of Jun 12, 2020: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$483,840
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John R. Beaver · Executive Officer
  • Todd A. Norbe · Executive Officer, Director
  • Elaine C. Wagner · Director
  • Garrett T. Sato · Director
  • Jess T. Roper · Director
  • Jonathan T. Lord · Director
  • Michael C. DiTolla · Director
  • Richard B. Lanman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · broker-dealer The Benchmark Company LLC (CRD 22982) · New York, New YorkSold in CA, IL, KY, NY
  • Colliers Securities LLC (CRD 7477) · Minneapolis, MinnesotaSold in CA, IL, KY, NY

Remarks in the notice

  • On the amounts: “Combined purchase price of 10,800,000 shares of common stock (CS) in a registered direct offering & warrants in private placement to purchase 10,800,000 shares of CS with an exercise price of $0.515 per share.”

Signed by John R. Beaver, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 12, 2020. Read the notice at the SEC.

equity, optionsSEC
Oct 2019$4 MNo. 2$2 to $10 million

Biolase Technology Inc.: Raise no. 2, Oct 2019

Investors in this round

4 investors had bought by the notice of Nov 5, 2019: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John R. Beaver · Executive Officer
  • Todd A. Norbe · Executive Officer, Director
  • Elaine C. Wagner, D.D.S. · Director
  • Garrett T. Sato · Director
  • Jess T. Roper · Director
  • Jonathan T. Lord, M.D. · Director
  • Richard B. Lanman, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Todd A. Norbe, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 5, 2019. Read the notice at the SEC.

equitySEC
Jun 2011$9 MNo. 1$2 to $10 million

Biolase Technology Inc.: Raise no. 1, Jun 2011

Investors in this round

7 investors had bought by the notice of Jul 11, 2011: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
$451,200
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Federico Pignatelli · Executive Officer, Director
  • Frederick D Furry · Executive Officer
  • Alexander K Arrow · Director
  • Gregory E Lichtwardt · Director
  • Norman J Nemoy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Rodman & Renshaw, LLC · New York, New YorkSold in IL, NY, TX

Signed by Federico Pignatelli, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 11, 2011. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Biolase Technology Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2023).

    SEC Form D · Dec 2023

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Dec 2023

That is all the official record says: Biolase Technology Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Biolase Technology Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Biolase Technology Inc.
NameRoleNamed in
Jennifer R. BrightExecutive officerDec 2023
John R. BeaverExecutive officerDec 2023
Todd A. NorbeExecutive officerJun 2020
Federico PignatelliExecutive officerJul 2011
Frederick D FurryExecutive officerJul 2011
Carol Gomez SummerhaysDirectorDec 2023
Jess T. RoperDirectorDec 2023
John R. BeaverDirectorDec 2023
Jonathan R. LordDirectorDec 2023
Kathleen T. O'LoughlinDirectorDec 2023
Kenneth P. YaleDirectorDec 2023
Martha T. SomermanDirectorDec 2023
Elaine C. WagnerDirectorJun 2020
Garrett T. SatoDirectorJun 2020
Jonathan T. LordDirectorJun 2020
Michael C. DiTollaDirectorJun 2020
Richard B. LanmanDirectorJun 2020
Todd A. NorbeDirectorJun 2020
Elaine C. Wagner, D.D.S.DirectorNov 2019
Jonathan T. Lord, M.D.DirectorNov 2019
Richard B. Lanman, M.D.DirectorNov 2019
Alexander K ArrowDirectorJul 2011
Federico PignatelliDirectorJul 2011
Gregory E LichtwardtDirectorJul 2011
Norman J NemoyDirectorJul 2011